Gene Mutation in Parkinson's Patients Increases Cancer Risk

Share this content:

the Neurology Advisor take:

Patients with Parkinson’s disease who have LRRK2 G2019S mutations have an increased risk for cancer, especially hormone-related cancer and breast cancer in women, according to a study published in JAMA Neurology.

Lead researcher Ilir Agalliu, MD, ScD, of the Albert Einstein College of Medicine in the Bronx, and colleagues found that the mutation increased the overall risk for non-skin cancers, a risk for which previous evidence has been inconsistent.

The study included 1,549 patients with Parkinson's disease (PD) from five movement disorder clinics located in Europe, Israel, and the United States. Out of these patients, 11.4% had the LRRK2 G2019S mutation. Those who had the mutation were younger at the time of their PD diagnosis, 53.1% were women, and 76.8% were of Ashkenazi Jewish descent.

The primary outcome of the study was all cancers combined, non-skin cancers, smoking-related cancers, hormone-related cancers, and other types of cancer.

The researchers found that mutation carriers had significantly increased risks for non-skin cancer (OR, 1.62; 95% CI, 1.04-2.52), hormone-related cancers (OR, 1.87; 95% CI, 1.07-3.26) and breast cancer (OR, 2.34; 95% CI, 1.05-5.22) in comparison with those without the mutation. There were no associations with other cancers.

The researchers believe that further research is needed to investigate associations between LRRK2 mutations and cancer among patients with PD in order to better understand the underlying genetic susceptibility.

DNA
Gene Mutation in Parkinson's Patients Increases Cancer Risk

Patients with Parkinson disease (PD) who harbor LRRK2 G2019S mutations may have increased risks of nonskin cancers. However, the results have been inconsistent across studies.

Ilir Agalliu, MD, ScD, of the Albert Einstein College of Medicine in the Bronx, and colleagues analyzed pooled data from 5 centers to further examine the association betweenLRRK2 G2019S mutation and cancer among patients with PD and to explore factors that could explain discrepancies.

This multinational study from 5 centers demonstrates that LRRK2G2019S mutation carriers have an overall increased risk of cancer, especially for hormone-related cancer and breast cancer in women.

READ FULL ARTICLE From archneur.jamanetwork.com
You must be a registered member of Neurology Advisor to post a comment.
close

Next Article in Neurodegenerative Diseases

Sign Up for Free e-newsletters



CME Focus